Experimental drug NU-9 reduces toxic amyloid in early Alzheimer’s
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
List view / Grid view
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
New preclinical data on ACI-19626, a first-in-class PET tracer for imaging TDP-43 pathology, shows potential to greatly improve early diagnosis and treatment of multiple neurodegenerative diseases.
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
A new blood-brain barrier-crossing platform enables the delivery of therapeutic molecules to the brain, offering potential treatments for ALS and Alzheimer’s disease.
Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
A new phenomenon in the brain that could explain the development of early stages of neurodegeneration has been discovered which could lead to a future target for drug therapies for ALS.
Researchers have made discoveries about the formation of cellular components called membraneless organelles and the key role these organelles play in cells...
New approach for testing for ALS may be useful to reverse debilitating disease...
Drug delivery through the blood-brain barrier has shown to be difficult to overcome, but researchers may have discovered a method to overcome this issue...
Researchers have found another common thread linking nearly all of the TNR expansion diseases...